Ipsen – Consolidated Financial Statements – 2022

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Half-year statement of IPSEN liquidity agreement – 2024 06 30

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis